Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation*.

Angewandte Chemie (International ed. in English) - 27 Sept 2021

Su Xiaoxuan, Ma Wenxiao, Feng Di, Cheng Boyang, Wang Qian, Guo Zefeng, Zhou Demin, Tang Xinjing

Abstract excerpt

There is an urgent need to develop antiviral drugs and alleviate the current COVID-19 pandemic. Herein we report the design and construction of chimeric oligonucleotides comprising a 2'-OMe-modified antisense oligonucleotide and a 5'-phosphorylated 2'-5' poly(A)4 (4A2-5 ) to degrade envelope and spike RNAs of SARS-CoV-2. The oligonucleotide was used for searching and recognizing target viral RNA sequence, and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chlorocebus aethiops
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endoribonucleases

Share to Hydrolysis

Share to Oligonucleotides, Antisense

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Share to Vero Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 34278671
DOI: 10.1002/anie.202105942
PMCID: PMC8426974

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation*.PMID 34278671Read ↗

Inhibition of SARS-CoV-2 by Targeting Conserved Viral RNA Structures and SequencesSemantic proximity Read ↗

A Promising Strategy Against SARS-CoV-2 Infected Patients: Antisense TherapySemantic proximity Read ↗

<strong>Think Different with RNA Therapy: Can Antisense Oligonucleotides Be Used to Inhibit Replication and Transcription of SARS-Cov-2?</strong>Semantic proximity Read ↗

Antisense oligonucleotide: A promising therapeutic option to beat COVID ‐19Semantic proximity Read ↗

Structural and Functional RNA Motifs of SARS-CoV-2 and Influenza A Virus as a Target of Viral InhibitorsSemantic proximity Read ↗

XNAzymes targeting the SARS-CoV-2 genome inhibit viral infectionSemantic proximity Read ↗

Efficient Targeted Delivery of Bifunctional Circular Aptamer ASO Chimera to Suppress the SARS-CoV-2 Proliferation and InflammationSemantic proximity Read ↗

Aptamer‐based strategies against SARS‐CoV‐2 virusesSemantic proximity Read ↗

Antisense Oligonucleotide-Based Therapy of Viral InfectionsSemantic proximity Read ↗

Delivery strategies for RNA-targeting therapeutic nucleic acids and RNA-based vaccines against respiratory RNA viruses: IAV, SARS-CoV-2, RSVSemantic proximity Read ↗

Elucidating the effect of a rationally designed nanostructured form-switching ASO (NaFASO) for targeting long non-coding RNA to alleviate Japanese encephalitis virus infectionSemantic proximity Read ↗

Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino-oligomersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.